The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell ...

ORLANDO — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new ...

Lemon is one of two pet therapists at Golisano, the other is Dorian, a goldendoodle. Their roles at the children’s hospital, ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

Hydrotherapy significantly improved balance and reduced fatigue in MS patients compared to standard physiotherapy, enhancing daily function and energy levels. The study used the Modified Fatigue ...

Lemon is one of two pet therapists at Golisano, the other is Dorian, a goldendoodle. Their roles at the children’s hospital, ...

Local institutions led studies on AI coaching for diabetes, psychedelic treatments for postpartum depression, and music ...

The past year also saw IWS open a $30 million facility in North Arlington that is considered one of the most advanced ...

Researchers sought to determine whether adding fixed-duration venetoclax to RBAC in the first line would be effective in older patients with high-risk MCL.

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines of therapy, with no new safety signals emerging over time.